Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes

Sunjaya, Anthony Paulo; Halim, Samuel; Ferdinal, Frans

doi:10.1055/s-0036-1572523

Cited by 6 publications

(8 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the use of rosuvastatin, pravastatin, atorvastatin, simvastatin and fluvastatin was associated with a decreased DLC risk (Table 2 and Figure 2). Although mechanisms underlying the effect of statins on DLC risk in patients with T2DM remain unclear, the complex mechanism underlying HMG‐CoA inhibition involves both lipid metabolism regulation and insulin utilization 44 . Statins affect glucose control through various pathways, such as the regulation of insulin production and secretion by β‐pancreatic cells, insulin resistance, insulin uptake by muscles and adipocytes and adipokine production 44 .…”

Section: Discussionmentioning

confidence: 99%

“…Although mechanisms underlying the effect of statins on DLC risk in patients with T2DM remain unclear, the complex mechanism underlying HMG‐CoA inhibition involves both lipid metabolism regulation and insulin utilization 44 . Statins affect glucose control through various pathways, such as the regulation of insulin production and secretion by β‐pancreatic cells, insulin resistance, insulin uptake by muscles and adipocytes and adipokine production 44 . Thus, by potentially delaying the progression of diabetes to NAFLD/NASH, the use of statins may contribute to reducing the risk of DLC in patients with T2DM.…”

Section: Discussionmentioning

confidence: 99%

“…44 Statins affect glucose control through various pathways, such as the regulation of insulin production and secretion by β-pancreatic cells, insulin resistance, insulin uptake by muscles and adipocytes and adipokine production. 44 Thus, by potentially delaying the progression of diabetes to NAFLD/NASH, the use of statins may contribute to reducing the risk of DLC in patients with T2DM.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM

Chen

Chiang

et al. 2023

Liver International

View full text Add to dashboard Cite

Background and AimsNon‐alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and poses a significant threat to patients with type 2 diabetes mellitus (T2DM) and metabolic dysregulation. Statins exert anti‐inflammatory, antioxidative and antithrombotic effects that target mechanisms underlying NAFLD. However, the protective effects of the different doses, intensities and types of statins on the incidence of NAFLD‐related decompensated liver cirrhosis (DLC) in patients with T2DM remain unclear.MethodsThis study used the data of patients with T2DM who were non‐HBV and non‐HCV carriers from a national population database to examine the protective effects of statin use on DLC incidence through propensity score matching. The incidence rate (IR) and incidence rate ratios (IRRs) of DLC in patients with T2DM with or without statin use were calculated.ResultsA higher cumulative dose and specific types of statins, namely rosuvastatin, pravastatin, atorvastatin, simvastatin and fluvastatin, reduced the risk of DLC in patients with T2DM. Statin use was associated with a significant reduction in the risk of DLC (HR: .65, 95% CI: .61–.70). The optimal daily intensity of statin use with the lowest risk of DLC was .88 defined daily dose (DDD).ConclusionsThe results revealed the protective effects of specific types of statins on DLC risk in patients with T2DM and indicated a dose–response relationship. Additional studies are warranted to understand the specific mechanisms of action of different types of statins and their effect on DLC risk in patients with T2DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM

Chen

Chiang

et al. 2023

Liver International

View full text Add to dashboard Cite

show abstract

“…Moreover, missing rates of related variables were very low (0.04%). Finally, although we adjusted for several potential confounders in our analysis, residual confounding may remain due to unmeasured or uncontrolled confounders such as statins use that might affect blood glucose control [30].…”

Section: No Of Deaths N (%) Hba1c In Participants Without Known Diabetesmentioning

confidence: 99%

Association between haemoglobin A1c and all-cause and cause-specific mortality in middle-aged and older Koreans: a prospective cohort study

et al. 2022

View full text Add to dashboard Cite

Background This study aimed to examine associations between haemoglobin A1c (HbA1c) levels over time and all-cause and cause-specific mortality in middle-aged and older Koreans. Methods Using 16 years of follow-up data from the Korean Genome and Epidemiology Study, we analysed 9294 individuals aged 40–69 years with no history of cardiovascular disease (CVD) or cancer. Participants were divided into a known diabetes group and five groups categorized by HbA1c levels (< 5.0%, 5.0–5.4%, 5.5–5.9%, 6.0–6.4%, and ≥ 6.5%). Hazard ratios (HRs) for all-cause and cause-specific mortality associated with HbA1c levels were calculated using a conventional and a time-dependent Cox proportional hazards model. Restricted cubic spline models were fitted to investigate the relationship between continuous HbA1c levels and mortality among people without known diabetes. Subgroup analyses were performed for age, sex, smoking, hypertension, liver diseases, and red blood cell counts. Results During a median follow-up period of 15.7 years, there were 944 deaths, including 185 deaths from CVD, 359 from cancer, and 125 from all external causes. Compared with participants with HbA1c levels of 5.5–5.9%, multivariate-adjusted HRs and 95% confidence intervals for all-cause death of participants with levels < 5.0%, 5.0–5.4%, 6.0–6.4%, and ≥ 6.5% and participants with known diabetes were 1.84 (1.35–2.51), 1.13 (0.95–1.34), 1.30 (1.04–1.62), 1.37 (0.97–1.93), and 2.03 (1.70–2.44), respectively. The risk of cancer mortality was significantly increased in HbA1c < 5.0% (HR, 2.21; 95% CI 1.42–3.44) and known diabetes (HR, 1.60; 95% CI 1.18–2.15). When we performed diverse subgroup analyses, low HbA1c levels at baseline were strongly associated with mortality in participants with liver diseases. Conclusions We found U-shaped associations between HbA1c levels at baseline and over time and all-cause mortality in middle-aged and older Koreans. Additionally, the risk of cancer mortality increased both in low and high HbA1c groups, but CVD mortality increased only in high HbA1c group. In particular, people with liver diseases and low HbA1c levels had a high risk of all-cause mortality. Therefore, more careful management of these groups is suggested to identify any deteriorating health conditions. Graphical abstract

show abstract

“…On the other hand, pravastatin and fluvastatin appeared to exert a neutral or possibly favorable effect on glycemic control, although further studies are required to confirm this. 49 …”

Section: Statinsmentioning

confidence: 99%

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus

Kosmas

Silverio²,

Sourlas

et al. 2018

DIC

View full text Add to dashboard Cite

Lipid-lowering therapy is used very commonly nowadays not only for the optimization of the lipid profile but also to reduce cardiovascular risk. However, some studies have linked the use of certain lipid-lowering agents with an increased risk for impaired glycemic control and new-onset diabetes mellitus, a condition well established as an important risk factor for cardiovascular disease. On the other hand, some other lipid-lowering agents have been shown to have a beneficial effect on glucose metabolism. Profound knowledge of these differences would enable the clinician to choose the right lipid-lowering medication for each individual patient, so that the benefits would outweigh the risk of side effects. This review aims to present and discuss the clinical and scientific data pertaining to the impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus.

show abstract

Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes

Cited by 6 publications

References 68 publications

Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM

Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM

Association between haemoglobin A1c and all-cause and cause-specific mortality in middle-aged and older Koreans: a prospective cohort study

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus

Contact Info

Product

Resources

About